NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Aera Therapeutics

Aera Therapeutics

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://aeratx.com/

Last Round

Series A

and B

Feb 16, 2023

Total Funding Raised

$193M

Company Overview

Aera Therapeutics is a biotechnology company that develops proprietary delivery platforms, including protein nanoparticles, lipid nanoparticles, and antibody-oligonucleotide conjugates, to enable transformative genetic medicines.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

genetic medicinein vivo CAR-Tdelivery platformprotein-based deliverybiotech platformautoimmune disease therapytLNPtargeted lipid nanoparticlesnext-gen CAR-Tdrug delivery techPNPprotein nanoparticleAOCantibody oligonucleotide conjugatebiotech pipeline

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aera Therapeutics Comparables

Compare Aera Therapeutics with similar companies based on industry and business-model similarity.

Aera Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Stylus Medicine
89%
Velvet Therapeutics
85%
Alaya.bio
84%

Aera Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series A and BFeb 16, 2023

Key People

Founding team and executive leadership

Akin Akinc

Chief Executive Officer

Executive Team

Paul Conrad

CBO And CFO

Executive Team

Aera Therapeutics Investors

Notable investors and investment history

Aera Therapeutics investors
InvestorRounds
GVSeries A and B
ARCH Venture PartnersSeries A and B
Lux CapitalSeries A and B
ARCH Venture PartnersSeries A and B

Market signals

Structured signals derived from secondary market and firmographic data.

  • Dec 2, 2025

    Presented data on AERA-109, a targeted In Vivo CAR-T therapy.

  • Dec 2, 2025

    Presenting preclinical data at the 67th ASH Annual Meeting.

Aera Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Aera Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Aera Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range88
Year Founded2021
Last FundingFeb 16, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.